A new review published recently in the British Journal of Cancer addresses appropriate current practice regarding the use of neoadjuvant and adjuvant androgen deprivation therapy (ADT) in combination with radiation therapy in the management of patients with high-risk localized and locally advanced forms of prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", ADT, androgen deprivation, localized, locally advanced, outcomes, radiation therapy, survival | 11 Comments »
In light of the publication this week of data by Warde et al. on external beam radiation therapy + lifelong total androgen deprivation (ADT) as a first-line treatment for high-risk, localized and locally advanced prostate cancer (click here for commentary), it is interesting to note an article from another research group outlining experience with a very different strategy. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: "high risk", localized, locally advanced, prostatectomy, robot-assisted | Leave a comment »
The big news today is the publication, in The Lancet, of the interim results of the NCIC CTG PR.3/MRC UK PR07 trial, originally presented by Warde et al. at the annual meeting of the American Society for Clinical Oncology in June 2010 and then by Mason et al. at the annual meeting of the American Society for Radiation Oncology (ASTRO) that September. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: "high risk", ADT, androgen deprivation therapy, EBRT, external beam radiation therapy, localized, locally advanced | Leave a comment »
A fascinating new paper based on data from the Prostate Cancer DataBase Sweden provides important insight into the consequences of delayed diagnosis and potential under-treatment of men who are diagnosed with locally advanced prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: delayed, Diagnosis, locally advanced, mortality, prostate cancer-specific | 14 Comments »
A new analysis of information from the Swedish national prostate cancer registry database and the Swedish cause of death register has confirmed the importance of aggressive, curative treatment of men with locally advanced prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: locally advanced, mortality, prostate cancer-specific, Sweden | 1 Comment »
For many years surgery was considered to be inappropriate for most men with locally advanced prostate cancer — most particularly those with positive lymph nodes (TxN1Mx) at the time of surgery. … READ MORE …
Filed under: Diagnosis, Management, Treatment | Tagged: "high risk", localized, locally advanced, node-positive, surgery | Leave a comment »
The use of androgen deprivation therapy (ADT) is at the heart of treatment for patients with advanced forms of prostate cancer. What has been debated for years, however, is when, for how long, and in combination with what other forms of therapy ADT should be applied. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adjuvant, ADT, androgen deprovation therapy, local therapy, locally advanced, outcome | 9 Comments »
It is clear from a report in the December issue of Urologic Oncology that the neoadjuvant use of chemohormonal therapy prior to surgery or radiation is not going to be a “cure-all” for prostate cancer patients initially diagnosed with high-risk, locally advanced prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", chemotherapy, locally advanced, neoadjuvant | Leave a comment »
An important article by Bolla et al. has been published in the New England Journal of Medicine today, together with editorial comment by Albertsen. We advise readers to study this article in conjunction with a second article published today under the heading “Hormone therapy and radiation treatment: a topical update.” … READ MORE …
Filed under: Management, Treatment | Tagged: adjuvant, hormone, locally advanced, radiation, therapy | Leave a comment »
A group at the Cleveland Clinic has reported the results of a small, single-arm, Phase II trial of neoadjuvant albumin-bound paclitaxel (nab-paclitaxel or neoadjuvant Abraxane®), given prior to radical prostatectomy in high risk, locally advanced patients. Prior comparable studies with neoadjuvant docetaxel have demonstrated a PSA response but have shown no obvious antitumor activity. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: "high risk", Abraxane, locally advanced, neoadjuvant, paclitaxel | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 